Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users

被引:85
作者
Knowlton, A
Arnsten, J
Eldred, L
Wilkinson, J
Gourevitch, M
Shade, S
Dowling, K
Purcell, D
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD 21205 USA
[2] Albert Einstein Coll Med, Div Gen Internal Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Bronx, NY 10467 USA
[4] US Hlth Resources & Serv Adm, Special Projects Natl Significance, HIV AIDS Bur, Rockville, MD 20857 USA
[5] Univ Miami, Leonard M Miller Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33152 USA
[6] NYU, Sch Med, Div Gen Internal Med, New York, NY USA
[7] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94143 USA
[8] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD 21205 USA
[9] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA
关键词
HIV/AIDS; illicit injection drug users; antiretroviral effectiveness; social support; patient-provider communication; stable housing; African American;
D O I
10.1097/01.qai.0000186392.26334.e3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among individuals receiving highly active antiretroviral therapy (HAART), injection drug users (IDUs) are less likely to achieve HIV suppression. The present Study examined individual-level, interpersonal, and structural factors associated with achieving undetectable plasma viral load (UVL) among US IDUs receiving recommended HAART. Data were from baseline assessments of the INSPIRE (Interventions for Seropositive Injectors-Research and Evaluation) study, a 4-site, secondary HIV prevention intervention for heterosexually active IDUs. Of 1113 study participants at baseline, 42% (n = 466) were currently taking recommended HAART (34% were female, 69% non-Hispanic black, 26% recently homeless; median age was 43 years), of whom 132 (28%) had a UVL. Logistic regression revealed that among those on recommended HAART, adjusted odds of UVL were at least 3 times higher among those with high social support, stable housing, and CD4 > 200; UVL was approximately 60% higher among those reporting better patient-provider communication. Outpatient drug treatment and non-Hispanic black race and an interaction between current drug use and social support were marginally negatively significant. Among those with high perceived support, noncurrent drug users compared with current drug users had a greater likelihood of current drug use was not associated with UVL among those with low support. Depressive symptoms (Brief Symptom Inventory) were not significant. Results suggest the major role of social support in facilitating effective HAART use in this population and suggest that active drug use may interfere with HAART use by adversely affecting social support. Interventions promoting social support functioning, patient-provider communication, stable housing, and drug abuse treatment may facilitate effective HAART use in this vulnerable population.
引用
收藏
页码:486 / 492
页数:7
相关论文
共 51 条
[1]  
Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
[2]   Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users [J].
Arnsten, JH ;
Demas, PA ;
Grant, RW ;
Gourevitch, MN ;
Farzodegan, H ;
Howard, AA ;
Schoenboum, EE .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (05) :377-381
[3]   Relationships between perception of engagement with health care provider and demographic characteristics, health status, and adherence to therapeutic regimen in persons with HIV/AIDS [J].
Bakken, S ;
Holzemer, WL ;
Brown, MA ;
Powell-Cope, GM ;
Turner, JG ;
Inouye, J ;
Nokes, KM ;
Corless, IB .
AIDS PATIENT CARE AND STDS, 2000, 14 (04) :189-197
[4]   Gender differences in factors associated with adherence to antiretroviral therapy [J].
Berg, KM ;
Demas, PA ;
Howard, AA ;
Schoenbaum, EE ;
Gourevitch, MN ;
Arnsten, JH .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2004, 19 (11) :1111-1117
[5]   Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility study [J].
Broadhead, RS ;
Heckathorn, DD ;
Altice, FL ;
van Hulst, Y ;
Carbone, M ;
Friedland, GH ;
O'Connor, PG ;
Selwyn, PA .
SOCIAL SCIENCE & MEDICINE, 2002, 55 (02) :235-246
[6]   Failure to maintain adherence to HAART in a cohort of french HIV-positive injecting drug users [J].
Carrieri, MP ;
Chesney, MA ;
Spire, B ;
Loundou, A ;
Sobel, A ;
Lepeu, G ;
Moatti, JP .
INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2003, 10 (01) :1-14
[7]   Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease [J].
Catz, SL ;
Kelly, JA ;
Bogart, LM ;
Benotsch, EG ;
McAuliffe, TL .
HEALTH PSYCHOLOGY, 2000, 19 (02) :124-133
[8]  
*CDCP, 2002, HIV AIDS SURV REP
[9]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[10]   Time to initiating highly active antiretroviral therapy among HIV infected injection drug users [J].
Celentano, DD ;
Galai, N ;
Sethi, AK ;
Shah, NG ;
Strathdee, SA ;
Vlahov, D ;
Gallant, JE .
AIDS, 2001, 15 (13) :1707-1715